Chimeric receptor genes and cells transformed therewith

US8211422B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• YEDA RESEARCH AND DEVELOPMENT CO. LTD. · IL

Inventors

• Zelig Eshhar · Rehovot, IL
• Daniel Schindler · Newton, US
• Tova Waks · Netanya, IL
• Gideon Gross · Rosh Pina, IL
• Steven A. Rosenberg · Potomac, US
• Patrick Hwu · Houston, US

Key dates

• Filing date: Oct 24, 1995
• Grant date: Jul 3, 2012
• Expiry date: Dec 18, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2799/027
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.